Advertisement


Patricia A. Ganz, MD, on Breast Cancer: Whole- vs Partial-Breast Irradiation

2019 ASCO Annual Meeting

Advertisement

Patricia A. Ganz, MD, of NRG Oncology and Jonsson Comprehensive Cancer Center at UCLA, discusses the NRG/NSABP phase III findings, which showed that partial-breast irradiation was more convenient and resulted in less fatigue but slightly poorer cosmesis at 36 months in patients who did not receive chemotherapy (Abstract 508).



Related Videos

Bladder Cancer

Brian C. Baumann, MD, on Locally Advanced Bladder Cancer: Adjuvant Radiotherapy After Radical Cystectomy

Brian C. Baumann, MD, of Washington University School of Medicine, discusses study findings suggesting postoperative radiotherapy may be an option for patients with locally advanced bladder cancer after radical cystectomy who are unable or unwilling to use adjuvant chemotherapy (Abstract 4507).

 

Breast Cancer
Immunotherapy

Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Atezolizumab Plus Nab-paclitaxel

Hope S. Rugo, MD, of the University of California, San Francisco, and Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, discuss an update of the IMpassion130 interim overall survival analysis of atezolizumab plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (Abstract 1003).

Lung Cancer

Hirotsugu Kenmotsu, MD, on Nonsquamous Non–Small Cell Lung Cancer: Pemetrexed Plus Cisplatin vs Vinorelbine Plus Cisplatin

Hirotsugu Kenmotsu, MD, of Shizuoka Cancer Center, discusses the phase III JIPANG trial findings, which showed that pemetrexed plus cisplatin was not superior to vinorelbine plus cisplatin in terms of recurrence-free survival for patients with completely resected nonsquamous non–small cell lung cancer (Abstract 8501).

Head and Neck Cancer
Immunotherapy

Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab

Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase III results that support pembrolizumab with and without platinum-based chemotherapy plus fluorouracil as new first-line standards of care for recurrent or metastatic head and neck squamous cell carcinoma (Abstract 6000).

Prostate Cancer

Kim N. Chi, MD, on Castration-Resistant Prostate Cancer: Cabazitaxel vs Abiraterone or Enzalutamide in the Metastatic Setting

Kim N. Chi, MD, of BC Cancer, discusses updated results from a phase II study of cabazitaxel vs abiraterone or enzalutamide in patients with poor-prognosis metastatic castration-resistant prostate cancer (Abstract 5003).

Advertisement

Advertisement




Advertisement